NEW YORK (GenomeWeb News) –GenapSys said today that it has raised $37 million in a Series B financing round to support commercialization of its next-generation sequencing platform.

The Series B financing includes new investors Yuri Milner, Stanford StartX Fund, and other private and institutional investors.

The Redwood City, Calif.-based company is developing a next-gen sequencing system called GENIUS 110, which stands for Gene Electronic Nano-Integrated Ultra-Sensitive.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.